KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Receivables (2018 - 2025)

Historic Receivables for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $49.5 million.

  • Castle Biosciences' Receivables fell 154.99% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 154.99%. This contributed to the annual value of $51.2 million for FY2024, which is 3372.15% up from last year.
  • As of Q3 2025, Castle Biosciences' Receivables stood at $49.5 million, which was down 154.99% from $52.3 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Receivables ranged from a high of $56.4 million in Q1 2025 and a low of $14.3 million during Q1 2021
  • Over the past 5 years, Castle Biosciences' median Receivables value was $31.3 million (recorded in 2023), while the average stood at $33.7 million.
  • Per our database at Business Quant, Castle Biosciences' Receivables plummeted by 210.96% in 2021 and then soared by 6315.39% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Receivables stood at $17.3 million in 2021, then skyrocketed by 35.84% to $23.5 million in 2022, then skyrocketed by 63.15% to $38.3 million in 2023, then surged by 33.72% to $51.2 million in 2024, then fell by 3.39% to $49.5 million in 2025.
  • Its Receivables stands at $49.5 million for Q3 2025, versus $52.3 million for Q2 2025 and $56.4 million for Q1 2025.